Bioventus Inc. (BVS) Cash Flow Statement
Bioventus Inc. (BVS) generated $96.9M of operating cash flow over the twelve months to 2026-06-30, spent $2.6M on capital expenditure and had free cash flow of $94.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BVSBioventus Inc.Follow BVS — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 16 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.02 | -0.01 | 0.02 | 0.04 | 0.07 | 0.10 | |
| Capital expenditure | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | 0.01 | -0.02 | 0.01 | 0.04 | 0.07 | 0.09 | |
| Stock-based compensation | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | — |
USD billions · SEC XBRL
Bioventus Inc. — questions
- What is Bioventus Inc.'s operating cash flow?
- $96.9M over the twelve months to 2026-06-30.
- How much does Bioventus Inc. spend on capital expenditure?
- $2.6M over the twelve months to 2026-06-30.
- What is Bioventus Inc.'s free cash flow?
- $94.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Bioventus Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.